• Explore /
  • Poster
  • / E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

Abstract Poster

Authors

null

Howard S. Hochster

Department of Medical Oncology, Yale University School of Medicine, New Haven, CT

Howard S. Hochster , Paul J. Catalano , Edith P. Mitchell , Deirdre Jill Cohen , Peter J. O'Dwyer , Al Bowen Benson III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01079780

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3665)

DOI

10.1200/jco.2014.32.15_suppl.tps3665

Abstract #

TPS3665

Poster Bd #

119B

Abstract Disclosures

Similar Posters

First Author: Howard S. Hochster

First Author: Ying Liu

First Author: Kanwal Pratap Singh Raghav

First Author: Tomohiro Kondo